Supplementary Materials

Supplementary Material for:

A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity

Lisa M. Johansen, Lisa Evans DeWald, Charles J. Shoemaker, Benjamin G. Hoffstrom, Calli M. Lear-Rooney, Andrea Stossel, Elizabeth Nelson, Sue E. Delos, James A. Simmons, Jill M. Grenier, Laura T. Pierce, Hassan Pajouhesh, Joseph Lehár, Lisa E. Hensley, Pamela J. Glass, Judith M. White, Gene G. Olinger*

*Corresponding author. E-mail: gene.olinger{at}nih.gov

Published 3 June 2015, Sci. Transl. Med. 7, 290ra89 (2015)
DOI: 10.1126/scitranslmed.aaa5597

This PDF file includes:

  • Table S3. Survival of ma-EBOV–infected C57BL/6 mice after treatment with additional priority active compounds identified in vitro.
  • Fig. S1. Comparison of compound activity in the antiviral assay against eGFPEBOV infection versus uninfected host cell proliferation.
  • Fig. S2. Confirmatory in vitro eight-point dose-response curves for active compounds from EBOV antiviral screen in Vero E6 cells.
  • Fig. S3. Additional confirmatory in vitro eight-point dose-response curves for active compounds from EBOV antiviral screen in Vero E6 cells.
  • Fig. S4. Confirmatory in vitro eight-point dose-response curves for active compounds from EBOV antiviral screen in HepG2 cells.
  • Fig. S5. Additional confirmatory in vitro eight-point dose-response curves for active compounds from EBOV antiviral screen in HepG2 cells.
  • Fig. S6. Evaluation of sertraline and bepridil on endosome acidification.
  • Fig. S7. Evaluation of sertraline and bepridil on EBOV-VLP–GP1,2 trafficking to NPC1+ endolysosomes.
  • Fig. S8. Bepridil and sertraline, at the indicated concentrations, do not inhibit the viability of 293AD cells.
  • Fig. S9. Assessment of bepridil and sertraline on VSV EBOV-GP pseudovirion entry into parental and NPC1-overexpressing CHO cell lines.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Results of a three-point dose antiviral screen of 2635 compounds against eGFP-EBOV infection (two Excel files).
  • Table S2. Active compounds identified from preliminary three-point dose antiviral screen against eGFP-EBOV infection (Excel file).

[Download Tables S1 and S2]